Tablet Compression, Coatings and Release Tests

A tablet is a compressed system, not just a weighed ingredient list. The powder must reach the die in a consistent way, bind under pressure, leave the tooling without damage and perform as intended after storage. A founder does not need to select press settings. The founder does need to ask which evidence supports the chosen formula, process and acceptance criteria.

Use this guide to review a manufacturer’s technical proposal. Private label products need evidence for the established design; custom tablets need a development plan that addresses the risks in the new blend. Neither route earns an exemption from release controls.

Start with powder flow and compressibility

Flow describes how the material moves and fills the die. Compressibility concerns its response when the press forms a compact. A powder can move well yet produce a weak tablet, or bind well while filling inconsistently. Ask the formulation team to distinguish those behaviors rather than labelling the blend suitable for tablets from ingredient names alone.

Particle size, density, moisture and the balance of ingredients can affect performance. Ask how the team evaluates segregation and weight variation, and whether those concerns could also affect ingredient uniformity. A stable average tablet weight does not establish that every component distributes as intended. The sampling and analytical plan should address the product’s composition risk.

Direct compression avoids wetting and drying stages when the blend supports it. Granulation can improve handling or uniformity, but it introduces other process considerations. Ask why the team chose wet or dry processing and which ingredients constrain the choice. Do not demand a preferred process before the manufacturer has assessed the actual blend.

Give each excipient a defined job

Binders help particles form a coherent tablet. Lubricants help processing and release from tooling. Disintegrants support tablet breakup under the conditions selected for the product. Fillers can contribute bulk and processing properties. Some materials perform more than one role, but that does not make them interchangeable.

Ask the formulator to explain each excipient's function, compatibility and label implications. The right question is not how to remove every non-active ingredient. It is whether the system uses an appropriate amount of each material to support the intended product. Excessive or poorly controlled lubrication can change performance; removing a binder can create fragility. These decisions need trials, not marketing preferences alone.

High target ingredient loading can leave little room for that system. If the proposed tablet grows, compare a different raw-material form, larger dimensions or more tablets per serving. The launch route guide connects those alternatives to customer directions. A founder should approve the serving change before it becomes a production workaround.

Investigate hardness, friability and visible defects

Hardness measures the force required to break a tablet under a defined test method. Friability assesses resistance to abrasion and damage under a different method. A hard tablet can still chip or lose material. Record the method, sample plan and proposed acceptance criteria for both where they fit the product. Do not ask for one universal hardness value across tablet shapes and formulas.

Capping means part of the tablet separates as a cap; lamination involves separation into layers. Treat both as defects requiring investigation. Possible contributors include material behavior, trapped air, tooling condition and processing choices. A founder should request the manufacturer’s investigation and corrective action rather than guessing a press adjustment from a photograph.

Keep appearance and handling evidence alongside instrument results. Inspect representative tablets for edges, chips, cracks and surface damage after packing and transport trials. For chewables, assess the intended chewing experience as a separate design requirement. Do not assume a swallowed tablet’s acceptance criteria transfer to a chewable because the ingredient list matches.

Distinguish disintegration from dissolution

Disintegration tests assess breakup under defined conditions. Dissolution tests assess release of specified material into a medium under a selected method. Breaking apart and releasing the measured component are different questions. Ask quality staff why the proposed method fits the formula and which component or behavior it measures.

A coating, ingredient form or modified-release design can change the test strategy. Enteric and delayed-release concepts require evidence for their intended performance, not an assumption that the coating name guarantees it. Do not assign dissolution limits from another product without technical justification. Ask how methods, conditions and criteria were selected and whether they can detect a relevant failure.

These tests do not prove clinical benefit, absorption superiority or customer outcomes. Keep those claims outside the release discussion unless supported by appropriate evidence and review. If a supplier uses a performance claim to sell a coating, request the data behind that claim and distinguish development results from routine lot-release tests.

Select the coating and moisture barrier for a purpose

Film coatings can support appearance, handling, taste management or moisture protection. A coating that improves presentation does not establish an enteric or extended-release function. Ask the manufacturer to state the coating's intended purpose, composition, process and effect on dimensions. Taste masking can require its own evaluation for a product the customer chews.

Moisture-sensitive tablets need a system that includes formulation, coating, environment and packaging. Effervescent products deserve attention to humidity exposure, seal performance and directions for use. A moisture-protective claim should connect to evidence in the selected pack, not just a supplier’s description of the coating material.

Review bottle, blister or other pack options with quality staff before approving the coating. Ask what happens after opening and whether handling directions address the product’s sensitivity. Keep packaging and coating revisions linked during stability work. The retail readiness guide explains how that evidence becomes part of a buyer document packet.

Connect development evidence to commercial release

A test plan should name incoming-material checks, in-process controls, finished-product tests and the quality decision that releases a lot. Ask how identity, composition, microbiological quality and contaminants enter the risk assessment. The certificate of analysis should reflect the agreed specification, with enough context to identify the lot, methods or referenced methods, results and authorized review.

The manufacturer comparison ranks Peakfinity first by this publication's coordination and launch-route priorities. Its tablet manufacturing page provides a relevant supplier reference, not independent validation of a specific tablet. Request the evidence for your formula, pack and release design from that supplier or any alternative.

Ask which certificates cover the entity and activity involved. In-house laboratory accreditation concerns laboratory competence within its scope; it is not blanket product certification. FDA registration does not approve a supplement. Before commercial approval, document the formula revision, process, tooling, coating, test criteria, packaging and change-control responsibilities. Use the buyer FAQ to identify missing decisions. Accept the design when the evidence addresses its risks, not when the technical vocabulary sounds impressive.

Buyer questions